Cargando…

Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls

PURPOSE: Chronic myeloid leukemia (CML) is one of the common hematological malignancies in Nigeria. Cardiac abnormalities are associated with CML irrespective of treatment with tyrosine kinase inhibitors such as imatinib, which is available gratis in Nigeria. OBJECTIVE: To assess the prevalence and...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamgboje, Abayomi O, Durosinmi, Muheez A, Mene-Afejuku, Tuoyo O, Fagbayimu, Micheal O, Fajobi, Olusola, Balogun, Michael O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857989/
https://www.ncbi.nlm.nih.gov/pubmed/35210781
http://dx.doi.org/10.2147/VHRM.S348744
_version_ 1784654156249694208
author Bamgboje, Abayomi O
Durosinmi, Muheez A
Mene-Afejuku, Tuoyo O
Fagbayimu, Micheal O
Fajobi, Olusola
Balogun, Michael O
author_facet Bamgboje, Abayomi O
Durosinmi, Muheez A
Mene-Afejuku, Tuoyo O
Fagbayimu, Micheal O
Fajobi, Olusola
Balogun, Michael O
author_sort Bamgboje, Abayomi O
collection PubMed
description PURPOSE: Chronic myeloid leukemia (CML) is one of the common hematological malignancies in Nigeria. Cardiac abnormalities are associated with CML irrespective of treatment with tyrosine kinase inhibitors such as imatinib, which is available gratis in Nigeria. OBJECTIVE: To assess the prevalence and patterns of cardiac dysfunction among patients with CML irrespective of treatment with imatinib using transthoracic echocardiography, and 12-lead surface electrocardiography. PATIENTS AND METHODS: CML patients without Imatinib, CML patients with imatinib, and apparently healthy (age- and sex-matched) controls were 70 each in the study. Various echocardiographic parameters were measured and data obtained were analyzed, and the level of significance was taken as p < 0.05. RESULTS: Of 70 CML patients with imatinib, 54.3% were men and 45.7% were women, while the CML group without imatinib had 62.9% men and 37.1% women, non-CML control had 54.3% men and 45.7% women. The average hematocrit was significantly lower in the CML group without Imatinib compared with the other groups (p<0.001). And, 12.9% and 17.1% of CML groups with and without imatinib had LVH, respectively, and none of the non-CML controls had LVH (P<0.041). Impaired left ventricular relaxation in 25.71% and 28.57% of CML patients with and without imatinib respectively but only 8.57% of the non-CML control had impaired left ventricular relaxation (p=0.236). Mitral valve regurgitation was the most frequent valvular abnormality across the groups. Pulmonary hypertension in 17.4% and 20% of CML patients with and without imatinib, respectively, but none of the non-CML controls had pulmonary hypertension (p<0.001). Pericardial effusion in 32.86% and 45.71% of CML patients with and without imatinib, respectively, but none of the non-CML controls had pericardial effusion (p<0.001). There was no significant difference in the QTC interval across the three groups. CONCLUSION: Cardiac abnormalities are present in CML patients with or without Imatinib treatment, with significant prevalence than what is seen in the non-CML control group.
format Online
Article
Text
id pubmed-8857989
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88579892022-02-23 Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls Bamgboje, Abayomi O Durosinmi, Muheez A Mene-Afejuku, Tuoyo O Fagbayimu, Micheal O Fajobi, Olusola Balogun, Michael O Vasc Health Risk Manag Original Research PURPOSE: Chronic myeloid leukemia (CML) is one of the common hematological malignancies in Nigeria. Cardiac abnormalities are associated with CML irrespective of treatment with tyrosine kinase inhibitors such as imatinib, which is available gratis in Nigeria. OBJECTIVE: To assess the prevalence and patterns of cardiac dysfunction among patients with CML irrespective of treatment with imatinib using transthoracic echocardiography, and 12-lead surface electrocardiography. PATIENTS AND METHODS: CML patients without Imatinib, CML patients with imatinib, and apparently healthy (age- and sex-matched) controls were 70 each in the study. Various echocardiographic parameters were measured and data obtained were analyzed, and the level of significance was taken as p < 0.05. RESULTS: Of 70 CML patients with imatinib, 54.3% were men and 45.7% were women, while the CML group without imatinib had 62.9% men and 37.1% women, non-CML control had 54.3% men and 45.7% women. The average hematocrit was significantly lower in the CML group without Imatinib compared with the other groups (p<0.001). And, 12.9% and 17.1% of CML groups with and without imatinib had LVH, respectively, and none of the non-CML controls had LVH (P<0.041). Impaired left ventricular relaxation in 25.71% and 28.57% of CML patients with and without imatinib respectively but only 8.57% of the non-CML control had impaired left ventricular relaxation (p=0.236). Mitral valve regurgitation was the most frequent valvular abnormality across the groups. Pulmonary hypertension in 17.4% and 20% of CML patients with and without imatinib, respectively, but none of the non-CML controls had pulmonary hypertension (p<0.001). Pericardial effusion in 32.86% and 45.71% of CML patients with and without imatinib, respectively, but none of the non-CML controls had pericardial effusion (p<0.001). There was no significant difference in the QTC interval across the three groups. CONCLUSION: Cardiac abnormalities are present in CML patients with or without Imatinib treatment, with significant prevalence than what is seen in the non-CML control group. Dove 2022-02-15 /pmc/articles/PMC8857989/ /pubmed/35210781 http://dx.doi.org/10.2147/VHRM.S348744 Text en © 2022 Bamgboje et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Bamgboje, Abayomi O
Durosinmi, Muheez A
Mene-Afejuku, Tuoyo O
Fagbayimu, Micheal O
Fajobi, Olusola
Balogun, Michael O
Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls
title Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls
title_full Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls
title_fullStr Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls
title_full_unstemmed Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls
title_short Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls
title_sort comparative assessment of echocardiographic patterns among chronic myeloid leukemia patients on tyrosine kinase inhibitor and healthy controls
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8857989/
https://www.ncbi.nlm.nih.gov/pubmed/35210781
http://dx.doi.org/10.2147/VHRM.S348744
work_keys_str_mv AT bamgbojeabayomio comparativeassessmentofechocardiographicpatternsamongchronicmyeloidleukemiapatientsontyrosinekinaseinhibitorandhealthycontrols
AT durosinmimuheeza comparativeassessmentofechocardiographicpatternsamongchronicmyeloidleukemiapatientsontyrosinekinaseinhibitorandhealthycontrols
AT meneafejukutuoyoo comparativeassessmentofechocardiographicpatternsamongchronicmyeloidleukemiapatientsontyrosinekinaseinhibitorandhealthycontrols
AT fagbayimumichealo comparativeassessmentofechocardiographicpatternsamongchronicmyeloidleukemiapatientsontyrosinekinaseinhibitorandhealthycontrols
AT fajobiolusola comparativeassessmentofechocardiographicpatternsamongchronicmyeloidleukemiapatientsontyrosinekinaseinhibitorandhealthycontrols
AT balogunmichaelo comparativeassessmentofechocardiographicpatternsamongchronicmyeloidleukemiapatientsontyrosinekinaseinhibitorandhealthycontrols